Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.
OBJECTIVE
The introduction of long-acting injection antipsychotic agents has been associated with better treatment persistence and better subsequent patient outcomes. However, limited empirical data are available on patient outcomes resulting from the initiation of long-acting injectable antipsychotic agents. In this study, we assessed patterns of health-care utilization following the initiation of risperidone long-acting therapy (RLAT), the first and only second generation long-acting injectable antipsychotic agent, in schizophrenia patients within the Veterans Health Administration.


METHODS
Patients were identified if they initiated RLAT between 1 October 2005 and 30 September 2006, were ≥ 18 years of age at the time of initiation, and had at least four injections following the initiation. Paired t-tests and McNemar tests were used to compare patterns of health services use during 12 months pre- and post-initiation.


CONCLUSIONS
Among 924 eligible study subjects, about 94% were male with mean age of 51·1 years and as high as 60% had >3 and 29% had >5 comorbid conditions. The initiators of RLAT had an average of 17·3 (SD ± 9·7) injections within the 12 months following the initiation, with an average of 14 days between injections. Between the pre- and post-initiation periods, although the number of psychiatric-related outpatient visits increased from 24·6 to 39·1 (P < 0·001), the number of psychiatric hospitalizations decreased from 1·4 to 1·0 (P < 0·001) with an average length of stay reducing from 20 to 14 days (P < 0·001). The percentage of patients who experienced at least one or two psychiatric-related hospitalizations decreased from 68·9% to 45·7% (P < 0·001) and from 34·9% to 24·4% (P < 0·001), respectively.


CONCLUSIONS
Despite the values of RLAT in treating patients with schizophrenia, RLAT is largely underutilized in routine clinical practice. This observation highlights the importance for future research to ascertain the cost-effectiveness of initiating RLAT, especially the extent to which medication adherence influences the prescription pattern of RLAT and subsequent costs of initiating RLAT.
Center for the Assessment of Pharmaceutical Practices, Boston University School of Public Health, Boston, MA, USA. xsren@bu.edu
X S
XS
Ren
C
C
Crivera
M
M
Sikirica
R
R
Dirani
S
S
Qian
L E
LE
Kazis
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000453:epidemiology; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D015897:Comorbidity; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D003863:Depression / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology; D057286:Electronic Health Records; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008605:Mental Health Services; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital / Q000706:statistics & numerical data; D015995:Prevalence; D018967:Risperidone / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology / Q000628:therapy; D014481:United States; D014493:United States Department of Veterans Affairs
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D018967:Risperidone